Editorial Board About Us

Androgen deprivation therapy

All articles from this key word are listed below.

Volume 6, Supplement 8 Supplement

Androgen Deprivation Therapy: A Cornerstone in the Treatment of Advanced Prostate Cancer

Michael K Brawer

Androgen deprivation therapy Hormone therapy Mortality rates

Volume 6, Number 4 Review Articles

High-Grade Prostatic Intraepithelial Neoplasia

Diagnostic Review

Junqi Qian Lina Liu David G Bostwick Michael K Brawer

Prostate cancer Androgen deprivation therapy Prostatic intraepithelial neoplasia Alpha-methylacyl-CoAracemase

Volume 7, Supplement 3 Review Articles

Prostatic Intraepithelial Neoplasia: An Overview

Michael K Brawer

Prostate cancer Androgen deprivation therapy Biopsy Chemoprevention Repeat biopsy Prostatic intraepithelial neoplasia (PIN)High-grade PIN Epidemiology

Volume 9, Number 4 Review Articles

Estrogenic Side Effects of Androgen Deprivation Therapy

Treatment Update

Celestia Higano Matthew R Smith Michael G Oefelein Theresa A Guise James A Eastham Michael S Cookson

Androgen deprivation therapy (ADT) is part of standard therapy for locally advanced or metastatic prostate cancer and is frequently used in men with a rising prostate-specific antigen following radical prostatectomy or radiation therapy. In some men, ADT may be administered for years or even decades. The intended therapeutic effect of ADT is testosterone deficiency. Because estrogen is a normal metabolite of testosterone, ADT also results in estrogen deficiency. ADT has a variety of adverse effects, many of which are primarily related to estrogen deficiency. Bone mineral density may decrease by 4% to 13% per year in men receiving ADT. The fracture rate for patients on ADT averages 5% to 8% per year of therapy. Hot flashes, gynecomastia, and breast tenderness are common side effects associated with ADT. In the clinic, minimum baseline testing should include weight measurement, blood pressure reading, and fasting lipid panel and serum glucose tests. Currently, there are no large outcome trials in men on ADT testing the available therapies for adverse effects. No therapies are specifically approved for treatment of adverse effects in men on ADT. Although some therapies can be used for a single indication (based upon small studies), there is currently no agent to treat the multiple estrogenic side effects of ADT. [Rev Urol. 2007;9(4):163-180]

Androgen deprivation therapy Cardiovascular disease Gynecomastia Osteoporosis fracture Male hot flashes

Volume 9, Supplement 1 Review Articles

Androgen Deprivation Therapy in the Treatment of Advanced Prostate Cancer

New Directions in the Management of Advanced Prostate Cancer

Mark A Perlmutter Herbert Lepor

This article reviews the issues and controversies relevant to the treatment of advanced prostate cancer with androgen deprivation therapy. Initially, diethylstilbestrol was used for achieving androgen deprivation, but was replaced by luteinizing hormone-releasing hormone (LHRH). Adverse events associated with LHRH agonists include the flare phenomenon, hot flashes, loss of libido, erectile dysfunction, depression, muscle wasting, anemia, and osteoporosis. Intermittent therapy has been advocated to reduce morbidity of treatment. The addition of an antiandrogen provides maximum androgen blockade. There remains controversy regarding the timing of the addition of an antiandrogen. Secondary hormonal therapies include antiandrogens, adrenal androgen inhibitors, and estrogens. [Rev Urol. 2007;9(suppl 1):S3-S8]

Androgen deprivation therapy LHRH agonists Advanced prostate cancer Diethylstilbestrol Maximum androgen blockade

Volume 10, Number 2 Review Articles

Managing Bone Loss and Bone Metastases in Prostate Cancer Patients: A Focus on Bisphosphonate Therapy

Treatment Update

Androgen deprivation therapy (ADT) and bone metastases are the most important risk factors for developing skeletal complications (eg, bone loss, pathologic fractures) in prostate cancer (PC) patients with locally advanced and metastatic disease. Bisphosphonates, which inhibit excessive osteoclast activity caused by ADT and bone metastases, have proven to be safe and effective in preventing skeletal complications and presently are the standard of care in patients with metastatic disease. Bisphosphonates should be considered for use in all PC patients with locally advanced disease initiating ADT for an intended duration of at least 1 year, especially those with a low baseline bone mineral density. [Rev Urol. 2008;10(2):99-110]

Prostate cancer Androgen deprivation therapy Skeletal-related events Bone metastasis Bone loss Bisphosphonates

Volume 11, Number 4 Review Articles

The Impact of Prostate Cancer and Hormonal Therapy on Bone

Management Review

Gerald L Andriole

Large-scale studies agree that the observed decline in prostate cancer mortality that began in the early 1990s, shortly after prostate-specific antigen testing was introduced in the United States, is most likely explained by more widespread treatment of prostate cancer, including hormonal therapy. Practitioners should be aware of the risk of the development of osteoporosis and of skeletal side effects related to hormonal therapy to optimize the care of men with prostate cancer.[Rev Urol. 2009;11(4):185-189 doi: 10.3909/riu0469]© 2009 MedReviews®, LLC

Androgen deprivation therapy Hormone deprivation therapy Bonedestruction Osteoporosis Osteopenia

Volume 12, Number 3 Meeting Reviews

Oncological Update: New Findings in Bladder and Prostate Cancer

Meeting Review

Alexander Farr Markus Margreiter Roman Herout Franklin E Kuehhas Bob Djavan

Highlights From the 25th Anniversary Congress of the European Association of Urology, April 16-20, 2010, Barcelona, Spain [Rev Urol. 2010;12(2/3):e129-e133 doi: 10.3909/riu0499]

Prostate cancer Androgen deprivation therapy Bladder cancer Radical prostatectomy Radical cystectomy Carcinoma in situ Anastomotic stricture

Volume 12, Number 1 Review Articles

Intermittent Androgen Deprivation Therapy: Redefining the Standard of Care?

Management Update

E David Crawford Neal D Shore

As a clinical strategy, intermittent androgen deprivation therapy (IADT) has the potential to minimize adverse events associated with continuous androgen deprivation therapy while providing comparable efficacy for patients with advanced prostate cancer. Because most studies supporting IADT to date have been somewhat small and underpowered, additional large, randomized, controlled trials are needed before this strategy becomes the standard of care.However, the potential advantages of IADT, which include improved quality of life, the theoretical possibility of delaying hormone resistance, and possible reduction in expenses to the patient and health care payers, suggest it is a strategy worth further exploration.[Rev Urol. 2010;12(1):1-11 doi: 10.3909/riu0490]

Prostate cancer Androgen deprivation therapy Prostate-specific antigen Testosterone Hormonal therapy

Volume 18, Number 4 Prostate Cancer Academy

Prostate Cancer Academy 2016: Presentation Summaries

[Rev Urol. 2016;18(4):205-213 doi:10.3909/riuPCA2016] © 2016 MedReviews®, LLC

Immunotherapy Androgen deprivation therapy Cancer screening Cancer, prostate Robotic simple prostatectomy Intensity-modulated radiation therapy